APA (7th ed.) Citation

Zhengda Pei, Zhengda Pei, Ningping Xiao, Ningping Xiao, Pei Yang, Pei Yang, & Pei Yang. (2023). Cost-effectiveness analysis of first-line tislelizumab plus chemotherapy for recurrent or metastatic nasopharyngeal cancer. Frontiers Media S.A..

Chicago Style (17th ed.) Citation

Zhengda Pei, Zhengda Pei, Ningping Xiao, Ningping Xiao, Pei Yang, Pei Yang, and Pei Yang. Cost-effectiveness Analysis of First-line Tislelizumab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Cancer. Frontiers Media S.A., 2023.

MLA (9th ed.) Citation

Zhengda Pei, et al. Cost-effectiveness Analysis of First-line Tislelizumab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Cancer. Frontiers Media S.A., 2023.